Dexcom Inc [DXCM] stock is trading at $88.78, up 1.51%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DXCM shares have gain 2.72% over the last week, with a monthly amount glided 9.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dexcom Inc [NASDAQ: DXCM] stock has seen the most recent analyst activity on February 03, 2025, when Redburn Atlantic upgraded its rating to a Buy and also boosted its price target to $115 from $85. Previously, Robert W. Baird upgraded its rating to Outperform on January 16, 2025, and elevated its price target to $104. On July 26, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $80 on the stock. JP Morgan downgraded its rating to a Neutral and decreased its price target to $75 on July 26, 2024. Redburn Atlantic initiated its recommendation with a Neutral and recommended $130 as its price target on May 30, 2024. RBC Capital Mkts started tracking with a Outperform rating for this stock on March 12, 2024, and assigned it a price target of $165.
Dexcom Inc [DXCM] stock has fluctuated between $62.34 and $142.00 over the past year. Currently, Wall Street analysts expect the stock to reach $110 within the next 12 months. Dexcom Inc [NASDAQ: DXCM] shares were valued at $88.78 at the most recent close of the market. An investor can expect a potential return of 23.9% based on the average DXCM price forecast.
Analyzing the DXCM fundamentals
Dexcom Inc [NASDAQ:DXCM] reported sales of 3.95B for the trailing twelve months, which represents a growth of 1.97%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.31 and Total Capital is 0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 87.57 points at the first support level, and at 86.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 89.42, and for the 2nd resistance point, it is at 90.07.
Ratios To Look Out For
For context, Dexcom Inc’s Current Ratio is 2.46. Also, the Quick Ratio is 2.12, while the Cash Ratio stands at 0.36. Considering the valuation of this stock, the price to sales ratio is 8.77, the price to book ratio is 17.52 and price to earnings (TTM) ratio is 53.22.
Transactions by insiders
Recent insider trading involved Sylvain Jereme M, EVP, Chief Financal Officer, that happened on Jan 29 ’25 when 2090.0 shares were sold. EVP, Strategy & Corporate Dev, Dolan Matthew Vincent completed a deal on Jan 29 ’25 to sell 1183.0 shares. Meanwhile, EVP, Chief HR Officer Stern Sadie sold 2093.0 shares on Jan 29 ’25.
